683 Capital Management Position in Aldeyra Therapeutics (ALDX) Has Raised as Stock Declined; Central Garden & Pet Company Class A (CENTA) Holder Frontier Capital Management Co Increased Its Stake by $389,462 as Valuation Declined

January 27, 2018 - By Peter Mason

683 Capital Management Llc increased its stake in Aldeyra Therapeutics Inc (ALDX) by 59.12% based on its latest 2017Q3 regulatory filing with the SEC. 683 Capital Management Llc bought 310,421 shares as the company’s stock declined 12.75% while stock markets rallied. The hedge fund held 835,514 shares of the health care company at the end of 2017Q3, valued at $6.02 million, up from 525,093 at the end of the previous reported quarter. 683 Capital Management Llc who had been investing in Aldeyra Therapeutics Inc for a number of months, seems to be bullish on the $142.43M market cap company. The stock increased 2.76% or $0.2 during the last trading session, reaching $7.45. About 95,971 shares traded. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) has declined 18.94% since January 27, 2017 and is downtrending. It has underperformed by 35.64% the S&P500.

Frontier Capital Management Co Llc increased its stake in Central Garden & Pet Company Class A (CENTA) by 2.19% based on its latest 2017Q3 regulatory filing with the SEC. Frontier Capital Management Co Llc bought 10,526 shares as the company’s stock declined 10.35% while stock markets rallied. The institutional investor held 492,089 shares of the consumer specialties company at the end of 2017Q3, valued at $18.30 million, up from 481,563 at the end of the previous reported quarter. Frontier Capital Management Co Llc who had been investing in Central Garden & Pet Company Class A for a number of months, seems to be bullish on the $2.07 billion market cap company. The stock decreased 0.65% or $0.26 during the last trading session, reaching $39.62. About 130,305 shares traded. Central Garden & Pet Company (NASDAQ:CENTA) has risen 73.49% since January 27, 2017 and is uptrending. It has outperformed by 56.79% the S&P500.

Frontier Capital Management Co Llc, which manages about $13.86B US Long portfolio, decreased its stake in Louisiana (NYSE:LPX) by 591,484 shares to 557,391 shares, valued at $15.09 million in 2017Q3, according to the filing. It also reduced its holding in Beacon Roofing Supply Inc. (NASDAQ:BECN) by 1.13M shares in the quarter, leaving it with 3.00M shares, and cut its stake in Benefitfocus Inc. (NASDAQ:BNFT).

Since September 19, 2017, it had 1 buying transaction, and 0 selling transactions for $1.45 million activity.

Investors sentiment increased to 3.13 in Q3 2017. Its up 1.46, from 1.67 in 2017Q2. It increased, as 3 investors sold ALDX shares while 5 reduced holdings. 11 funds opened positions while 14 raised stakes. 18.26 million shares or 145.50% more from 7.44 million shares in 2017Q2 were reported. Alphaone Invest Ltd Liability holds 0% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 725 shares. Vanguard Gp Incorporated has 471,031 shares for 0% of their portfolio. State Street Corp has 0% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 18,500 shares. Sphera Funds Limited holds 1.07% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 1.04 million shares. 8,000 were reported by Deutsche Financial Bank Ag. Fmr Ltd Liability holds 1.61M shares or 0% of its portfolio. Jane Street Gp Limited Liability Corporation owns 0% invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) for 10,961 shares. Weiss Multi stated it has 0.01% of its portfolio in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). New York-based Comml Bank Of Ny Mellon Corporation has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). 85,200 were reported by Renaissance Techs Ltd Llc. Royal Bank & Trust Of Canada has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). The Illinois-based Northern Trust Corp has invested 0% in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). Hightower Llc stated it has 29,650 shares. Ardsley Advisory Prtnrs invested in 39,552 shares. Barclays Public Ltd accumulated 3,400 shares or 0% of the stock.

Among 6 analysts covering Aldeyra Therapeutics Inc (NASDAQ:ALDX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aldeyra Therapeutics Inc had 13 analyst reports since August 13, 2015 according to SRatingsIntel. The stock has “Buy” rating by Canaccord Genuity on Wednesday, September 13. The company was initiated on Tuesday, September 8 by Cowen & Co. As per Wednesday, August 9, the company rating was maintained by H.C. Wainwright. The stock has “Buy” rating by Cowen & Co on Wednesday, August 9. Cowen & Co maintained it with “Buy” rating and $14.0 target in Thursday, September 14 report. The stock has “Buy” rating by Cantor Fitzgerald on Tuesday, October 24. As per Thursday, June 15, the company rating was maintained by H.C. Wainwright. On Thursday, November 9 the stock rating was maintained by Cantor Fitzgerald with “Buy”. As per Monday, September 26, the company rating was initiated by H.C. Wainwright. The stock has “Buy” rating by Stifel Nicolaus on Friday, July 1.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Peter Mason

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: